How many drug targets are there?
The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
For the past decade, the number of molecular targets for approved drugs has been debated. Here, we reconcile apparently contradictory previous reports into a comprehensive survey, and propose a consensus number of current drug targets for all classes of approved therapeutic drugs. One striking feature is the relatively constant historical rate of target innovation (the rate at which drugs against new targets are launched); however, the rate of developing drugs against new families is significantly lower. The recent approval of drugs that target protein kinases highlights two additional trends: an emerging realization of the importance of polypharmacology, and also the power of a gene-family-led approach in generating novel and important therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, G-protein-coupled receptors (GPCRs) are influenced by trafficking progress and then internalized in the cell membrane and recycled or degraded.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [127]
In the citing paper
“Covalent molecules may not be able to effectively target GPCRs during this turnover process [127].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [127]
Citations
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
The Pfam Protein Families Database
Bateman, A. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.276 · Cited by 14,000
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Murzin, A. G., Brenner, S. E., Hubbard, T., & Chothia, C. (1995) · Journal of Molecular Biology · doi:10.1016/s0022-2836(05)80134-2 · Cited by 7,012 · cited 1×
“Patterns in drug targets In order to identify the familial relationships between all drug targets, we analysed the presence of domains, using the SCO”
MethodDrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 1×
“drugs acted primarily through only 120 underlying molecular target”
BackgroundSelf-citationThe Pfam protein families database
Bateman, A. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh121 · Cited by 3,127
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967 · cited 1×
“Imatinib, originally developed as a highly selective inhibitor of c-AB”
BackgroundA small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892 · cited 1×
“(and which target association led to its first approval for chronic myeloid leukaemia), has subsequently been discovered to be have significant activity against several other clinically relevant kinases, such as c-KI”
Background
Research works printed but not linked: 1
- Christensen, C. M. The Innovator's Dilemma: When New Technologies Cause Great Firms to Fail (Harvard Business School Press, Cambridge, 1997).
Cited by
Items 401–500 of 1,024
Fang, B., Mane-Padros, D., Bolotin, E., Jiang, T., & Sladek, F. M. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks190 · Cited by 112
Anti-inflammatory and metabolic actions of FXR: Insights into molecular mechanisms
Hollman, D. A. A., Milona, A., van Erpecum, K. J., & van Mil, S. W. C. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.07.004 · Cited by 124
“Indeed, 13% of all FDA-approved drugs target nuclear receptors [6], and are used for treatment of a wide range of diseases, such as metabolic syndrome, inflammation, and cancer [7–10].”
Backgroundde Groot, G. W., Santonicola, M. G., Sugihara, K., Zambelli, T., Reimhult, E., Vörös, J., & Vancso, G. J. (2013) · ACS Applied Materials & Interfaces · doi:10.1021/am302820y · Cited by 111
Biased G Protein-Coupled Receptor Signaling: New Player in Modulating Physiology and Pathology
Bologna, Z., Teoh, J., Bayoumi, A., Tang, Y., & Kim, I. (2016) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2016.165 · Cited by 129
“States Food and Drug Administration (FDA)-approved drugs target GPCRs (Overington et al., 2006).”
BackgroundLuchini, A., & Vitiello, G. (2020) · Biomimetics · doi:10.3390/biomimetics6010003 · Cited by 134
“Indeed, more than 60% of the currently marketed drugs target components of the plasma membrane [87].”
BackgroundSchulz, J., Hartz, A. M. S., & Bauer, B. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000025 · Cited by 122
“Ligands of nuclear receptors are classified as hormones, vitamins, or xenobiotic endocrine disruptors (Overington et al., 2006).”
BackgroundTargeting Protein–Protein Interactions and Fragment-Based Drug Discovery
Valkov, E., Sharpe, T., Marsh, M., Greive, S., & Hyvönen, M. (2011) · Topics in Current Chemistry · doi:10.1007/128_2011_265 · Cited by 107
“Analyses of known human target proteins of currently marketed drugs has revealed that, in comparison to the whole proteome, the efforts are centred on a very limited set of targets and target classes [2].”
BackgroundCharacterization of the Drugged Human Genome
Lauss, M., Kriegner, A., Vierlinger, K., & Noehammer, C. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.8.1063 · Cited by 118
Stiving, A. Q., VanAernum, Z. L., Büsch, F., Harvey, S. R., Sarni, S. H., & Wysocki, V. H. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b05071 · Cited by 117
Verschueren, E., Husain, B., Yuen, K. C. Y., Sun, Y. E., Paduchuri, S., Şenbabaoğlu, Y., Lehoux, I. E., Arena, T. A., Wilson, B., Lianoglou, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.007 · Cited by 113
Jamali, A. A., Ferdousi, R., Razzaghi, S., Li, J., Safdari, R., & Ebrahimie, E. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.007 · Cited by 118
Prediction of intracellular exposure bridges the gap between target- and cell-based drug discovery
Mateus, A., Gordon, L. J., Wayne, G. J., Almqvist, H., Axelsson, H., Seashore-Ludlow, B., Treyer, A., Matsson, P., Lundbäck, T., West, A., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1701848114 · Cited by 103
High-throughput andin silicoscreenings in drug discovery
Phatak, S. S., STEPHAN, C. C., & Cavasotto, C. N. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903190961 · Cited by 124
“It is estimated that there are 266 human genome targets with approved drugs [21].”
BackgroundThe recombinant expression systems for structure determination of eukaryotic membrane proteins
He, Y., Wang, K., & Yan, N. (2014) · Protein & Cell · doi:10.1007/s13238-014-0086-4 · Cited by 135
“Aberrant expressions and activities of IMPs are associated with a variety of diseases such as cancer, Alzheimer’s disease, and metabolic diseases (Ishikawa et al., 2004; Sanders and Myers, 2004; Overington et al., 2006; Aisenbrey et al., 2008; Bkaily and Al-Khoury, 2014).”
BackgroundEvaluation of blockbuster drugs under the Rule-of-five
Giménez, B. G., dos Santos, M. S., Ferrarini, M., Fernandes, J. P. S., & Fernandes, J. P. S. (2010) · Die Pharmazie · doi:10.31083/ph.2010.9733 · Cited by 106
TMbed: transmembrane proteins predicted through language model embeddings
Bernhofer, M., & Rost, B. (2022) · BMC Bioinformatics · doi:10.1186/s12859-022-04873-x · Cited by 106
“Membrane proteins facilitate many essential processes, including regulation, signaling, and transportation, rendering them targets for most known drugs [4, 5].”
Cellular Uptake Mechanisms and Endosomal Trafficking of Supercharged Proteins
Thompson, D. B., Villaseñor, R., Dorr, B. M., Zerial, M., & Liu, D. R. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.06.014 · Cited by 106
“, 2008), resulting in a number of macromolecular human drugs (Overington et al., 2006).”
Gαi is required for carvedilol-induced β1 adrenergic receptor β-arrestin biased signaling
Wang, J., Hanada, K., Staus, D. P., Makara, M. A., Dahal, G. R., Chen, Q., Ahles, A., Engelhardt, S. H., & Rockman, H. A. (2017) · Nature Communications · doi:10.1038/s41467-017-01855-z · Cited by 105
“at the β1AR: (1) it is inert with respect to Gαs; (2) it recruits Gαi and converts the β1AR from a Gαs-coupled receptor to one that couples to Gαi; and (3) it activates classical β-arrestin-dependent signaling in a Gαi paradigm.”
BackgroundLabbé, C. M., Laconde, G., Kuenemann, M. A., Villoutreix, B. O., & Sperandio, O. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.003 · Cited by 104
GraDeR: Membrane Protein Complex Preparation for Single-Particle Cryo-EM
Hauer, F., Gerle, C., Fischer, N., Oshima, A., Shinzawa‐Itoh, K., Shimada, S., Yokoyama, K., Fujiyoshi, Y., & Stark, H. (2015) · Structure · doi:10.1016/j.str.2015.06.029 · Cited by 110
Membrane protein reconstitution into giant unilamellar vesicles: a review on current techniques
Jørgensen, I. L., Kemmer, G. C., & Pomorski, T. G. (2016) · European Biophysics Journal · doi:10.1007/s00249-016-1155-9 · Cited by 110
“2001) but also due to their importance as pharmaceutical targets: approximately 60 % of all drugs target membrane proteins of which integral membrane proteins constitute the largest group (Overington et al. 2006).”
The mechanism for ligand activation of the GPCR–G protein complex
Mafi, A., Kim, S., & Goddard, W. A. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2110085119 · Cited by 115
“Since ∼34% of all modern medicinal drugs (2, 3) act on one or more of the 800 human GPCRs (4), there is great interest in understanding how binding of a ligand elicits this signaling.”
BackgroundIdentification of an allosteric binding site for RORγt inhibition
Scheepstra, M., Leysen, S., van Almen, G. C., Miller, J. R., Piesvaux, J., Kutilek, V. D., van Eenennaam, H., Zhang, H., Barr, K., Nagpal, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms9833 · Cited by 115
“This combination of characteristics of NRs has given rise to some of the most notable pharmaceutical agents of the past century 2 .”
Exploring the Evolution of Novel Enzyme Functions within Structurally Defined Protein Superfamilies
Furnham, N., Sillitoe, I., Holliday, G. L., Cuff, A. L., Laskowski, R. A., Orengo, C. A., & Thornton, J. M. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002403 · Cited by 112
“large number of approved drugs acting to modify the behaviour of enzymes implicated in human disease as well as disease causing pathogens [2].”
BackgroundThe oligomeric state sets GABAB receptor signalling efficacy
Comps‐Agrar, L., Kniazeff, J., Nørskov-Lauritsen, L., Maurel, D., Gassmann, M., Gregor, N., Prézeau, L., Bettler, B., Durroux, T., Trinquet, E., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.143 · Cited by 119
“Representing about 3% of encoding genes in mammals, these receptors constitute a major target in drug development (Overington et al, 2006; Lim, 2007).”
BackgroundLigand Binding Ensembles Determine Graded Agonist Efficacies at a G Protein-coupled Receptor
Böck, A., Bermúdez, M., Krebs, F., Matera, C., Chirinda, B., Sydow, D., Dallanoce, C., Holzgrabe, U., Amici, M. D., Lohse, M. J., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.735431 · Cited by 104
“Because of their abundance and relevance in regulating the majority of (patho-)physiological processes in humans, GPCRs have for a long time represented the most important drug targets being addressed by at least a third of all currentlymarketed drugs (6, 7).”
BackgroundApplication of computational methods for anticancer drug discovery, design, and optimization
Prada‐Gracia, D., Huerta‐Yépez, S., & Moreno‐Vargas, L. M. (2016) · Boletín Médico del Hospital Infantil de México · doi:10.1016/j.bmhimx.2016.10.006 · Cited by 119
“2,3 On the other hand, the number of organic molecules that can act as drugs is also a matter of debate More than 100 million small chemical compounds have been already synthesized for their screening on specific targets in public and private laboratories In addition, it is not only a matter of…”
Shameer, K., Glicksberg, B. S., Hodos, R., Johnson, K. W., Badgeley, M. A., Readhead, B., Tomlinson, M. S., O’Connor, T., Miotto, R., Kidd, B. A., et al. (2018) · Briefings in Bioinformatics · doi:10.1093/bib/bbw136 · Cited by 103
“Conserved sequence domains encoded in repurposed drug targets Conserved protein domains play a pivotal role in mediating function across various pathways and play a vital role in mediating functional and interaction promiscuity across protein families and aid in polypharmacology including drug repositioning [95].”
BackgroundChemoproteomic approaches to drug target identification and drug profiling
Bantscheff, M., & Drewes, G. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.11.003 · Cited by 124
The evolving small‐molecule fluorescent‐conjugate toolbox for C lass A GPCRs
Vernall, A. J., Hill, S. J., & Kellam, B. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12265 · Cited by 102
“GPCRs are 7-transmembrane spanning receptors, which account for nearly 4% of the proteinencoding human genome (Bjarnadóttir et al., 2006) and are the target of approximately 30% of all marketed drugs (Overington et al., 2006).”
X-ray structure breakthroughs in the GPCR transmembrane region
Topiol, S., & Sabio, M. L. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.02.012 · Cited by 119
“It is not surprising that the interest in applying such structure-based design methods to G-protein-coupled receptor (GPCR) targets [1], the largest single drug target class [2,3] has been sought for quite some time.”
BackgroundKirchmair, J., Markt, P., Distinto, S., Schuster, D., Spitzer, G. M., Liedl, K. R., Langer, T., & Wolber, G. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8005977 · Cited by 116
Back to the Future with Phenotypic Screening
Prior, M., Chiruta, C., Currais, A. J. M., Goldberg, J., Ramsey, J., Dargusch, R., Maher, P. A., & Schubert, D. A. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500051h · Cited by 115
Shim, J., & MacKerell, A. D. (2011) · MedChemComm · doi:10.1039/c1md00044f · Cited by 119
The G protein-coupled receptors deorphanization landscape
Laschet, C., Dupuis, N., & Hanson, J. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.02.016 · Cited by 112
Clifton, L. A., Campbell, R. A., Sebastiani, F., Terán, J. C., Gonzalez-Martinez, J. F., Björklund, S., Sotres, J., & Cárdenas, M. (2020) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2020.102118 · Cited by 112
Choy, B. C., Cater, R. J., Mancia, F., & Pryor, E. E. (2021) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2020.183533 · Cited by 100
“Given this, it is unsurprising that membrane proteins are the molecular targets of over 40% of all FDA approved drugs [2, 3], and that the determination of their three-dimensional structures is of paramount importance.”
BackgroundWen, P., Huang, H., Zhang, R., Zheng, H., Liang, T., Zhuang, C., Wu, Q., Wang, J., Liu, F., Zhang, K., et al. (2025) · Nature Chemistry · doi:10.1038/s41557-024-01705-8 · Cited by 113
“For instance, incorporating targeted molecules 33 on the surface of LLPS vehicles could open up the feasibility for other biomedical applications.”
A ‘rule of 0.5’ for the metabolite-likeness of approved pharmaceutical drugs
O’Hagan, S., Swainston, N., Handl, J., & Kell, D. B. (2014) · Metabolomics · doi:10.1007/s11306-014-0733-z · Cited by 109
“…(Lipinski et al. 1997) has been highly influential in this regard, but only about 50 % of orally administered new chemical entities actually obey it (Overington et al. 2006; Zhang and Wilkinson 2007) (and see Hopkins et al. 2014); indeed half of recent ‘new chemical entities’ are natural products…”
BackgroundXuan, P., Sun, C., Zhang, T., Ye, Y., Shen, T., & Dong, Y. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00459 · Cited by 100
“Through binding, drugs can either enhance or inhibit the expressions of genes and thereby affect disease processes (Overington et al., 2006; Yu et al., 2016; Santos et al., 2017).”
BackgroundPrediction of Chemical-Protein Interactions Network with Weighted Network-Based Inference Method
Cheng, F., Zhou, Y., Li, W., Liu, G., & Tang, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041064 · Cited by 100
“Most of drugs which selectively targeted kinases with high potency in vitro models are failure in the late stage of clinical trails due to side effects and lacking in vivo activities [54,55].”
BackgroundQuantitative Cell-Based Reporter Gene Assays Using Droplet-Based Microfluidics
Baret, J., Beck, Y., Billas, I. M. L., Moras, D., & Griffiths, A. D. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.04.010 · Cited by 107
“Ecdysone receptor agonists are used commercially as environmentally safe insecticides (Dhadialla et al., 1998; Sawada et al., 2003) and, more generally, compounds targeting nuclear receptors represent 13% of FDA-approved drugs (Overington et al., 2006).”
BackgroundLi, X., Zhu, L., Wang, B., Yuan, M., & Zhu, R. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00855 · Cited by 108
“Drugs targeting extracellular factors are prevalent, about 60% of known targets are receptors located on cell membrane mainly because the extracellular targets are accessible and serve as upstream signals (Overington et al., 2006), and so are the targets of fibrosisrelated drugs.”
BackgroundA systems-level framework for drug discovery identifies Csf1R as an anti-epileptic drug target
Srivastava, P. K., van Eyll, J. M., Godard, P., Mazzuferi, M., Delahaye‐Duriez, A., Steenwinckel, J. V., Gressèns, P., Danis, B., Vandenplas, C., Foerch, P., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06008-4 · Cited by 111
mCSM-membrane: predicting the effects of mutations on transmembrane proteins
Pires, D. E. V., Rodrigues, C. H. M., & Ascher, D. B. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa416 · Cited by 110
“Mutations in membrane proteins are associated with a wide variety of common diseases, including heart disease, and consequently have been the site of action for over 50% of small molecule drugs (1).”
BackgroundVemuri, K. V., Janero, D. R., & Makriyannis, A. (2007) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.11.012 · Cited by 115
“The etiology of many chronic diseases is multifactorial such that they cannot be treated effectively by one drug, even when that drug has broad-spectrum activity against several targets/ pathogenic processes [140].”
BackgroundGPCR-targeting nanobodies: attractive research tools, diagnostics, and therapeutics
Mujić-Delić, A., de Wit, R. H., Verkaar, F., & Smit, M. J. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.03.003 · Cited by 105
α-Helical transmembrane peptides: A “Divide and Conquer” approach to membrane proteins
Bordag, N., & Keller, S. (2009) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2009.07.009 · Cited by 116
Computational methods for drug design and discovery: focus on China
Zheng, M., Liu, X., Xu, Y., Li, H., Luo, C., & Jiang, H. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.08.004 · Cited by 116
“As of 2006, there were only 324 identified molecular targets for FDA-approved drugs [2].”
BackgroundKrasowski, A., Muthas, D., Sarkar, A., Schmitt, S., & Brenk, R. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci200266d · Cited by 99
Design Strategies for Bivalent Ligands Targeting GPCRs
Shonberg, J., Scammells, P. J., & Capuano, B. (2011) · ChemMedChem · doi:10.1002/cmdc.201100101 · Cited by 99
The design and development of covalent protein-protein interaction inhibitors for cancer treatment
Cheng, S.-S., Yang, G.-J., Wang, W., Leung, C.-H., & Ma, D.-L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00850-0 · Cited by 98
“Covalent molecules may not be able to effectively target GPCRs during this turnover process [127].”
BackgroundYeast two-hybrid methods and their applications in drug discovery
Hamdi, A., & Colas, P. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.10.008 · Cited by 114
Minimum information about a bioactive entity (MIABE)
Orchard, S., Al-Lazikani, B., Bryant, S., Clark, D., Calder, E., Dix, I., Engkvist, O., Forster, M., Gaulton, A., Gilson, M., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3503 · Cited by 98
Self-citationDASPfind: new efficient method to predict drug–target interactions
Ba-alawi, W., Soufan, O., Essack, M., Kalnis, P., & Bajic, V. B. (2016) · Journal of Cheminformatics · doi:10.1186/s13321-016-0128-4 · Cited by 99
“The drawback of these docking methods is that they require high-resolution X-ray crystal (3D) structures of proteins, which are not known for membrane-bound proteins, that account for more than 40 % of current drug targets [9, 10].”
BackgroundTargeting Nuclear Receptors with PROTAC degraders
Flanagan, J. J., & Neklesa, T. K. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110452 · Cited by 92
Gacche, R. N., & Meshram, R. J. (2013) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2013.10.001 · Cited by 107
“, 2002), pyroglutamic acid (Overington et al., 2006) and pyrophosphate (Berman et al.”
BackgroundProteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets
Knezevic, C. E., Wright, G., Remsing Rix, L. L., Kim, W., Kuenzi, B. M., Luo, Y., Watters, J. M., Koomen, J. M., Haura, E. B., Monteiro, A. N., et al. (2016) · Cell Chemical Biology · doi:10.1016/j.chembiol.2016.10.011 · Cited by 100
“Conversely, inhibition ofmultiple targets, including unintended/non-canonical targets, may also enhance overall efficacy (polypharmacology) or enable drug repurposing (Overington et al., 2006).”
Formation of Lipid-Bilayer Nanodiscs by Diisobutylene/Maleic Acid (DIBMA) Copolymer
Oluwole, A. O., Klingler, J., Danielczak, B., Babalola, J. O., Vargas, C., Pabst, G., & Keller, S. (2017) · Langmuir · doi:10.1021/acs.langmuir.7b03742 · Cited by 96
Impact of novel detergents on membrane protein studies
Lee, H. J., Lee, H. S., Youn, T., Byrne, B., & Chae, P. S. (2022) · Chem · doi:10.1016/j.chempr.2022.02.007 · Cited by 114
New drug discovery and development from natural products: Advances and strategies
Wang, Y., Wang, F., Liu, W., Geng, Y., Shi, Y., Yu, T., Zhang, B., Luo, Y., & Sun, X. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108752 · Cited by 113
Methods and Applications of Structure Based Pharmacophores in Drug Discovery
Pirhadi, S., Shiri, F., & Ghasemi, J. B. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026611313090006 · Cited by 97
“Currently, in spite of all the significant drug-development efforts performed, the number of successful drugs and novel targets is less than expectations during past decades [90-92].”
BackgroundRodriguez, G. J., Yao, R., Lichtarge, O., & Wensel, T. G. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914877107 · Cited by 99
“A full understanding of the mechanism for ligand discrimination is of intense interest given that 7TMRs make up about 30% of all therapeutic drugs (13).”
BackgroundHannedouche, S., Beck, V., Leighton-Davies, J., Beibel, M., Roma, G., Oakeley, E. J., Lannoy, V., Bernard, J., Hamon, J., Barbieri, S., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.497214 · Cited by 91
“As GPCRs make up one of the largest families of drug targets, there are many compounds known to modulate GPCR activity (34).”
BackgroundGoudet, C., Vilar, B., Courtiol, T., Deltheil, T., Bessiron, T., Brabet, I., Oueslati, N., Rigault, D., Bertrand, H., McLean, H., et al. (2012) · The FASEB Journal · doi:10.1096/fj.11-195941 · Cited by 104
“G-protein-coupled receptors (GPCRs) are a valuable class of target in therapeutic drug development (1).”
BackgroundLessons Learned from Two Decades of Anticancer Drugs
Liu, Z., Delavan, B., Roberts, R., & Tong, W. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.06.005 · Cited by 94
“There are fewer than 100 anticancer targets implicated in FDA-approved anticancer drugs, which is still a small proportion compared with the 20 000 human genes that encode approximately 500 000 proteins in the human genome [39,40].”
BackgroundBig Potassium (BK) ion channels in biology, disease and possible targets for cancer immunotherapy
Ge, L., Hoa, N. T., Wilson, Z., Arismendi-Morillo, G., Kong, X., Tajhya, R. B., Beeton, C., & Jadus, M. R. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.06.040 · Cited by 107
“Pharmacological research targeting these molecules are developing better drugs for many diseases [5].”
BackgroundFluorine-19 NMR of integral membrane proteins illustrated with studies of GPCRs
Didenko, T., Liu, J. J., Horst, R., Stevens, R. C., & Wüthrich, K. (2013) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2013.07.011 · Cited by 96
Environmental Designer Drugs: When Transformation May Not Eliminate Risk
Cwiertny, D. M., Snyder, S. A., Schlenk, D., & Kolodziej, E. P. (2014) · Environmental Science & Technology · doi:10.1021/es503425w · Cited by 110
Hydrophobicity scales: a thermodynamic looking glass into lipid–protein interactions
MacCallum, J. L., & Tieleman, D. P. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.08.003 · Cited by 103
Cell-Specific Aptamers as Emerging Therapeutics
Meyer, C., Hahn, U., & Rentmeister, A. (2011) · Journal of Nucleic Acids · doi:10.4061/2011/904750 · Cited by 108
Feng, Z., Alqarni, M. H., Yang, P., Tong, Q., Chowdhury, A., Wang, L., & Xie, X. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci5002718 · Cited by 107
Fronik, P., Gaiser, B. I., & Pedersen, D. S. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01601 · Cited by 103
Modulation of Gut Barrier Functions in Ulcerative Colitis by Hyaluronic Acid System
Kotla, N. G., Isa, I. L. M., Rasala, S., Demir, S., Singh, R., Baby, B. V., Swamy, S. K., Dockery, P., Jala, V. R., Rochev, Y. A., et al. (2021) · Advanced Science · doi:10.1002/advs.202103189 · Cited by 101
Photoactivatable Lipid Probes for Studying Biomembranes by Photoaffinity Labeling
Xia, Y., & Peng, L. (2013) · Chemical Reviews · doi:10.1021/cr300419p · Cited by 105
Fine-Tuning Multiprotein Complexes Using Small Molecules
Thompson, A. D., Dugan, A., Gestwicki, J. E., & Mapp, A. K. (2012) · ACS Chemical Biology · doi:10.1021/cb300255p · Cited by 92
“01% have been targeted with inhibitors (2, 6-8).”
BackgroundThe pathway of ligand entry from the membrane bilayer to a lipid G protein-coupled receptor
Stanley, N., Pardo, L., & Fabritiis, G. D. (2016) · Scientific Reports · doi:10.1038/srep22639 · Cited by 100
“∑ = − = = dP t dt k P t k P t K P t ( )/ ( ) ( ) ( ), (1) N”
Co(III)-Catalyzed Enaminone-Directed C–H Amidation for Quinolone Synthesis
Shi, P., Wang, L., Chen, K., Wang, J., & Zhu, J. S. (2017) · Organic Letters · doi:10.1021/acs.orglett.7b00968 · Cited by 93
Functional autoantibodies targeting G protein-coupled receptors in rheumatic diseases
Cabral-Marques, O., & Riemekasten, G. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.134 · Cited by 105
FXR: structures, biology, and drug development for NASH and fibrosis diseases
Tian, S., Chen, S., Pan, C., & Li, Y. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00849-4 · Cited by 102
“Indeed, NRs modulators account for more than 10% of all FDA-approved drugs [5].”
BackgroundHybrid Ortho/Allosteric Ligands for the Adenosine A1Receptor
Narlawar, R., Lane, J. R., Doddareddy, M. R., Lin, J., Brussee, J., & IJzerman, A. P. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901252a · Cited by 109
Ali, F., Ahmad, S., Swati, Z. N. K., & Akbar, S. (2019) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-019-00207-x · Cited by 93
Turning liabilities into opportunities: Off-target based drug repurposing in cancer
Palve, V. C., Liao, Y., Rix, L. L. R., & Rix, U. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.003 · Cited by 103
Johnston, J. M., & Filizola, M. (2011) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2011.06.008 · Cited by 102
Pogodin, P. V., Lagunin, A. A., Filimonov, D. A., & Poroikov, V. (2015) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2015.1078407 · Cited by 102
“Nonetheless, chemical space is practically endless [7], and the number of protein targets is slowly but surely increasing, along with our knowledge of biological systems [8].”
BackgroundAllosteric targeting of receptor tyrosine kinases
Smet, F. D., Christopoulos, A., & Carmeliet, P. (2014) · Nature Biotechnology · doi:10.1038/nbt.3028 · Cited by 102
Tang, M., Comellas, G., & Rienstra, C. M. (2013) · Accounts of Chemical Research · doi:10.1021/ar4000168 · Cited by 102
Mass spectrometry-enabled structural biology of membrane proteins
Calabrese, A. N., & Radford, S. E. (2018) · Methods · doi:10.1016/j.ymeth.2018.02.020 · Cited by 92
CETSA beyond Soluble Targets: a Broad Application to Multipass Transmembrane Proteins
Kawatkar, A., Schefter, M., Hermansson, N.-O., Snijder, A., Dekker, N., Brown, D. G., Lundbäck, T., Zhang, A. X., & Castaldi, M. P. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00399 · Cited by 96
Orthosteric/Allosteric Bitopic Ligands: Going Hybrid at GPCRs
Valant, C., Sexton, P. M., & Christopoulos, A. (2009) · Molecular Interventions · doi:10.1124/mi.9.3.6 · Cited by 108
“Owing to their ubiquitous cell surface distribution and their contributions to multiple physiological and pathophysiological processes, GPCRs have frequently been exploited as drug targets, currently accounting for around thirty percent of all medicines on the market (2).”
BackgroundJang, H. S., Na, Y., Hong, K., Lee, S. H., Moon, S., Cho, M., Park, M., Lee, O., Chang, E. M., Lee, D. R., et al. (2017) · Journal of Pineal Research · doi:10.1111/jpi.12432 · Cited by 92
Rondard, P., Goudet, C., Kniazeff, J., Pin, J., & Prézeau, L. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.08.009 · Cited by 113
Miao, Y., Goldfeld, D. A., Moo, E. V., Sexton, P. M., Christopoulos, A., McCammon, J. A., & Valant, C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612353113 · Cited by 89
“T largest group of signal-transmitting proteins at the cell surface is the superfamily of G protein-coupled receptors (GPCRs) (1) that account for targets of ∼40% of currently marketed drugs.”
BackgroundThe activities of drug inactive ingredients on biological targets
Pottel, J., Armstrong, D., Zou, L., Fekete, A., Huang, X., Torosyan, H., Bednarczyk, D., Whitebread, S., Bhhatarai, B., Liang, G., et al. (2020) · Science · doi:10.1126/science.aaz9906 · Cited by 96
Koole, C., Wootten, D., Simms, J., Miller, L. J., Christopoulos, A., & Sexton, P. M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.309328 · Cited by 87
“GPCRs(3) are the largest family of transmembrane (TM)-spanning proteins, accounting for 1% of the human genome, and are the leading target of marketed therapeutics (1, 2).”
BackgroundPhysiological relevance of GPCR oligomerization and its impact on drug discovery
Panetta, R., & Greenwood, M. T. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.09.002 · Cited by 92
Label-free quantification of membrane-ligand interactions using backscattering interferometry
Baksh, M. M., Kussrow, A. K., Mileni, M., Finn, M. G., & Bornhop, D. J. (2011) · Nature Biotechnology · doi:10.1038/nbt.1790 · Cited by 90
“Membrane-associated proteins and their interactions are therefore of paramount interest for drug discovery and development, accounting for almost 70% of existing drug target”
BackgroundStructuring Detergents for Extracting and Stabilizing Functional Membrane Proteins
Matar, R., Rhimi, M., Leydier, A., Huché, F., Galián, C., Mandon, E. D., Ficheux, D., Flot, D. M., Aghajari, N., Kahn, R., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018036 · Cited by 107
“Membrane proteins represent 20–30% of total proteins in all species [1] and up to 60% of pharmaceutical targets [2].”
BackgroundIdentification of Small-Molecule Frequent Hitters from AlphaScreen High-Throughput Screens
Schorpp, K., Rothenaigner, I., Salmina, E. S., Reinshagen, J., Low, T., Brenke, J. K., Gopalakrishnan, J., Tetko, I. V., Gul, S., & Hadian, K. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113516861 · Cited by 92
“This strategy included six steps: (1) development of primary assays, (2) HTS against 25,000 compounds for each assay, (3) data analysis and identification of frequent hitters that reduced the AlphaScreen signal in all assays irrespective of the PPI being investigated, (4) confirmation and counter screening of the freq…”
BackgroundMethodInfluentialGenetic and neuronal regulation of sleep by neuropeptide VF
Lee, D. A., Andreev, A., Truong, T. V., Chen, A., Hill, A. J., Oikonomou, G., Pham, U., Hong, Y. K., Tran, S., Glass, L., et al. (2017) · eLife · doi:10.7554/elife.25727 · Cited by 83
Metadata
- Authors
- Overington, J. P., Al-Lazikani, B., & Hopkins, A. L.
- Affiliations
- Pfizer (United Kingdom) (GB)
- Corresponding author
- Overington, John P.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-12
- Volume
- 5
- Issue
- 12
- Pages
- 993-996
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1968682237
- Cited by
- 3,505
- References
- 29
- Citations by year
- 2026: 82 · 2025: 126 · 2024: 117 · 2023: 127 · 2022: 173 · 2021: 168 · 2020: 190 · 2019: 190 · 2018: 198 · 2017: 215 · 2016: 276 · 2015: 268 · 2014: 245 · 2013: 280 · 2012: 247
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- therapeutic target, molecular targets, protein kinases, polypharmacology, approved drugs
- MeSH terms
- Humans, Technology, Pharmaceutical, Drug Design, Drugs, Investigational, Genome, Human, Drug Delivery Systems, Drug Approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.